Janssen strengthens immunotherapy capabilities with BeneVir acquisition – BioPharma-Reporter.com
BioPharma-Reporter.com |
Janssen strengthens immunotherapy capabilities with BeneVir acquisition
BioPharma-Reporter.com BeneVir is a biopharmaceutical company specializing in the development of oncolytic immunotherapies. Its proprietary T-Stealth Oncolytic Virus Platform is designed to infect and destroy cancer cells. “BeneVir will further enable the advancement of the … |
